Business Wire

Alibaba Challenges Students to Create Solutions for a Post Covid-19 World

Share

Innovative students from across 13 markets who want to help the world and be rewarded for their ingenuity will now have the chance.

This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20200420005302/en/

Alibaba Business School has announced the launch of Alibaba Global E-Commerce Talent (GET) Global Challenge 2020, aimed squarely at helping businesses and organizations worldwide recover faster and rebound stronger in the wake of the Covid-19 pandemic. The competition will empower the next generation of entrepreneurial talents to contribute by creating transformative digital solutions in collaboration with mentors and partners from the Alibaba network.

Targeted at university and higher education institution students from 13 markets including the African continent, China, Colombia, France, Indonesia, Malaysia, Mexico, the Philippines, Russia, Serbia, South Korea, Thailand and Uzbekistan, the competition will be conducted virtually and span four phases, starting this month. A minimum of 100 teams, each comprising three to five members, are expected to compete. Following national finals that will take place between June and August, over 30 teams will face off virtually in the World Finals from August 17 to 25, 2020.

“The pandemic is fast-becoming a generation-defining moment, especially for the incoming class of talents. We have collectively risen to the occasion with digital tools invented and repurposed to limit and mitigate the difficulties faced, and there is no better time to get our future talents to lend their creativity and digital savviness in helping the world to recover,” said Zhang Yu, Alibaba Group Partner and Vice President. “We have seen examples of how digital transformation can play a key role in reducing day-to-day struggles, improving work productivity and quality of life. We hope the challenge will spur the creation of even more life-changing solutions not just for now, but for the future as well.”

Teams submitting their business proposals will receive coaching and reference materials based on modern case studies and learning assets via Alibaba’s DingTalk live streaming sessions. These will be conducted by GET Network-certified experts and Alibaba-trained managers and eFounders, who are regular instructors for Alibaba Business School’s various existing digital training programs. Participants will have the opportunity to deepen their knowledge on digital economy topics ranging from digital transformation, customer-centricity, start-up landscape to pitching for investment and more. The top six teams who qualify for the world finals will also receive one-on-one coaching sessions.

The teams will be judged on the innovativeness of their proposal, ability to solve real-world problems, as well as the feasibility, sustainability, and scalability of their new ventures. The final six teams will receive two additional benefits in the form of business funding by Alibaba and the eligibility to join the global GET talent bank, which will provide even more support for their business endeavors. The winning team will also be granted a fully sponsored digital economy discovery trip to Alibaba’s headquarters in Hangzhou, including exclusive sessions with Alibaba GET Network trainers.

The Alibaba GET Network was initiated in 2018 as an extension of Alibaba’s GET program which, to date, has benefitted 80 education partners and trained more than 300 lecturers and over 13,000 students and other participants from Australia, India, Israel, Mongolia, Malaysia, Thailand, Turkey, South Korea, Singapore and China.

Interested participants can head to this link to know more details and find contact of country hosts:

https://bit.ly/2RyIzs8

About Alibaba Group

Alibaba Group’s mission is to make it easy to do business anywhere. The company aims to build the future infrastructure of commerce. It envisions that its customers will meet, work and live at Alibaba, and that it will be a company that lasts at least 102 years.

About Alibaba Business School

Alibaba Business School conducts training programs and workshops, with the vision of empowering the Digital Economy through education to share the positive impact of a new business paradigm in promoting inclusive development and to inspire and empower entrepreneurs, youth and women globally. These programs encourage entrepreneurs to share and use digital economy tools to create positive social impact and to collaborate with each other as well as the public sector to create larger impact. To date, there are over 500 digital entrepreneurs and business leaders from 28 countries trained directly by Alibaba Business School, who have subsequently shared with over 2 million policymakers, entrepreneurs, SME’s, practitioners and students in their own countries.

About the Alibaba GET Network

The Alibaba GET Network is part of Alibaba’s mission to make it easy to do business anywhere. By tapping into the resources and best practices from the Alibaba Group ecosystem worldwide, the initiative aims to share the positive impact of the new business paradigm of the digital economy and promote inclusive development to inspire and empower youth globally. The Alibaba GET Network is open to universities and educational institutions wanting to incorporate digital economy curriculum in the education and training system and develop young entrepreneurs and digital talents.

For more information about Alibaba GET Program, please visit https://get.alibaba.com

Contact information

Rico Ngai
Alibaba Group
+852 9725 9600
rico.ngai@alibaba-inc.com

About Business Wire

Business Wire
Business Wire



Subscribe to releases from Business Wire

Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.

Latest releases from Business Wire

Idriverplus Joins the “Automate with Velodyne” Ecosystem29.5.2020 20:31:00 CESTPress release

Velodyne Lidar, Inc. and Idriverplus today announced an expanded partnership and Idriverplus inclusion into the Automated with Velodyne integrator ecosystem, which helps companies grow their businesses while using Velodyne lidar technology. Through the program, Velodyne will further collaborate with Idriverplus to support its continued innovation and promote Idriverplus autonomous vehicles, including street cleaners, passenger cars and logistics vehicles. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20200529005589/en/ Velodyne Lidar, Inc. and Idriverplus announced an expanded partnership and Idriverplus inclusion into the Automated with Velodyne integrator ecosystem, which helps companies grow their businesses while using Velodyne lidar technology. (Photo: Velodyne Lidar) Recently, Velodyne signed a multi-year sales agreement with Idriverplus to provide Puck™ sensors for the mass production of autonomous vehicles. Idriverplu

Interim Data from the Open Label Phase 2 OPTIC Study of Iclusig ® (ponatinib) for Chronic Phase-CML Presented at the ASCO and EHA Virtual Meetings29.5.2020 14:00:00 CESTPress release

Incyte (Nasdaq:INCY) today announced that data from the interim analysis of the Phase 2 OPTIC (Optimizing Ponatinib Treatment In CML) trial, which was sponsored by Takeda and co-funded by Incyte, will be presented during an oral session at the upcoming 2020 American Society of Clinical Oncology Virtual Meeting (ASCO20; May 29 – May 31) (Abstract #7502)1; and at the virtual 25th Congress of the European Hematology Association (EHA25; June 11 – 14) (Abstract #S172)2. The OPTIC trial is an ongoing randomized, open-label study prospectively evaluating response-based dosing regimens of Iclusig® (ponatinib) over a range of three starting doses (45 mg, 30 mg, 15 mg) with the aim of optimizing its efficacy and safety in patients with chronic-phase chronic myeloid leukemia (CP-CML), who are resistant or intolerant to prior tyrosine kinase inhibitor (TKI) therapy. With a median follow up of approximately 21 months, data from the interim analysis of the OPTIC trial show that the optimal benefit-r

Takeda Receives Positive CHMP Opinion for Pre-Filled Syringe Presentation of TAKHZYRO ® (lanadelumab) for Use as a Preventive Treatment for Hereditary Angioedema Attacks29.5.2020 14:00:00 CESTPress release

Takeda Pharmaceutical Company Limited (TSE:4502/NYSE:TAK) (“Takeda”) today announced that the European Medicines Agency’s (EMA) Committee for Medicinal Products for Human Use (CHMP) has adopted a positive opinion on a Type II Variation regulatory application and recommended the approval of a pre-filled syringe presentation of TAKHZYRO® (lanadelumab). TAKHZYRO is a subcutaneous injectable prescription medication approved in Europe for routine prevention of recurrent attacks of hereditary angioedema (HAE) in patients aged 12 years and older. HAE is a rare genetic disorder that results in recurrent attacks of oedema – swelling – in various parts of the body, including the abdomen, face, feet, genitals, hands and throat.1,2,3 “Our goal is to continuously innovate in all areas of HAE management,” said Isabel Kalofonos, Global Product Strategy Lead, HAE, Takeda. “This positive opinion marks another important step forward as we aim to enhance the experience of treatment administration for peo

Takeda to Present Data from the ICLUSIG ® (ponatinib) Clinical Trial Program that Could Prove Practice-Changing for the Treatment of Chronic-Phase CML29.5.2020 14:00:00 CESTPress release

Takeda Pharmaceutical Company Limited (TSE:4502/NYSE:TAK) today announced that interim analysis data from the Phase 2 OPTIC (Optimizing Ponatinib Treatment In CML) trial will be presented during an oral session at the virtual 56thAmerican Society of Clinical Oncology (ASCO) Annual Meeting and the 25thEuropean Hematology Association (EHA) Annual Meeting. The OPTIC trial is an ongoing, randomized, open-label study prospectively evaluating response-based dosing regimens of ICLUSIG® (ponatinib) over a range of three starting doses (45-, 30-, or 15-mg) with the aim of optimizing its efficacy and safety in patients with chronic-phase chronic myeloid leukemia (CP-CML) who are resistant or intolerant to prior tyrosine kinase inhibitor (TKI) therapy. With a median follow-up of approximately 21 months, data from the interim analysis of OPTIC show that the optimal benefit-risk profile for ICLUSIG in patients with CP-CML is achieved with a daily starting dose of 45-mg and, upon achieving ≤1% BCR-A

Takeda Announces Compelling Data from the Phase 2 Trial of Pevonedistat Plus Azacitidine in Patients with Higher-Risk MDS29.5.2020 14:00:00 CESTPress release

Takeda Pharmaceutical Company Limited (TSE:4502/NYSE:TAK) today announced the results of the Phase 2 Pevonedistat-2001 trial will be presented during oral sessions at the virtual 56thAmerican Society of Clinical Oncology (ASCO) Annual Meeting and the virtual 25thEuropean Hematology Association (EHA) Annual Meeting. The study evaluated pevonedistat plus azacitidine versus azacitidine alone in patients with rare leukemias, including higher-risk myelodysplastic syndromes (HR-MDS). These results show that the combination of pevonedistat and azacitidine is a highly active, promising therapeutic approach and suggest benefit in the HR-MDS subgroup across multiple clinically meaningful endpoints, including overall survival (OS), event-free survival (EFS), complete remission (CR) and transfusion independence, with a safety profile similar to azacitidine alone. The Pevonedistat-2001 trial was designed as a proof-of-concept study in patients with HR-MDS, higher-risk chronic myelomonocytic leukemi

LetsGetChecked Debuts FDA EUA-Authorized At-Home Coronavirus (COVID-19) Sure-track Test29.5.2020 13:57:00 CESTPress release

LetsGetChecked, the leading direct-to-consumer at-home health testing and insights company, announces today the authorization of the new Coronavirus (COVID-19) Sure-track Test for at-home consumer use by the U.S. Food and Drug Administration under an EUA. The new test is authorized to serve at-risk individuals with a proprietary at-home PCR nasal swab test that delivers accurate and definitive results within 24 hours. Offering an end-to-end model, LetsGetChecked’s new Sure-track Test introduces the most complete FDA EUA-authorized Coronavirus at-home testing solution. The at-home Coronavirus (COVID-19) test incorporates a nasal swab and PCR lab analysis, offering convenient and secure results in 24 hours. Unlike serology tests that detect the presence of antibodies, the at-home COVID-19 test determines the presence or absence of SARS-CoV-2 viral RNA. LetsGetChecked’s Sure-track Test is the only FDA EUA-authorized at-home Coronavirus (COVID-19) test that owns all aspects of the testing

In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.

Visit our pressroom